Lymphocyte subset distribution can predict the efficacy of first-line treatment in patients with non-Hodgkin lymphoma.
Clinical Medicine and Pharmacology · 2026
DOI: 10.70731/1m330584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine and Pharmacology, 2026. Verfasst von Yumei Huang und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To explore the relationship between peripheral blood lymphocyte subsets and diffuse large B-cell lymphoma ( DBL) . large B-cell lymphoma , DLBCL and nasal NK/T-cell lymphoma (NK/T-cell) To investigate the relationship between first-line treatment efficacy and predictive biomarkers for DLBCL (Diagnosis Related-Brain Colopathy) and nasal ENKTL (Enzyme-Lung Cell Toxic Leukoma).
Methods
The basic pathological characteristics of 110 patients diagnosed with DLBCL or nasal ENKTL were analyzed, and the efficacy of first-line treatment regimens was evaluated. The correlations between peripheral blood lymphocyte subsets, tumor-specific growth factor ( TSGF ) , lactate dehydrogenase ( LDH ) , and Ki67 with the efficacy of first-line treatment for DLBCL and nasal ENKTL were also examined. P < 0.05 was considered statistically significant.
Results
1. DLBCL was more predominantly diagnosed at an advanced stage (III-IV), while nasal ENKTL was more predominantly diagnosed at an early stage (I) (P = 0.000 ). DLBCL was primarily treated with CHOP-containing regimens, while nasal ENKTL was primarily treated with GELOXD regimens (P = 0.000 ). DLBCL was predominantly associated with partial remission (PR), while nasal ENKTL was predominantly associated with complete remission (CR). Nasal ENKTL had a better prognosis (P = 0.005 ). 2. Stage, CD8 + T lymphocyte ratio , and LDH were independent risk factors for the efficacy of first-line treatment of DLBCL (higher levels indicate worse efficacy); while stage and T lymphocyte ratio were risk factors for the efficacy of first-line treatment with nasal ENKTL (higher levels indicate worse efficacy).
Conclusion
The distribution of peripheral blood lymphocyte subsets is closely related to the efficacy of first-line treatment for DLBCL and nasal ENKTL. By detecting the distribution of peripheral blood lymphocyte subsets before treatment, the efficacy of first-line treatment for DLBCL and nasal ENKTL can be predicted, thereby guiding physicians to adjust treatment plans.
Zitieren
APA
Huang, Y., Tan, Z., Deng, H., Huang, H., & Tang, F. (2026). Lymphocyte subset distribution can predict the efficacy of first-line treatment in patients with non-Hodgkin lymphoma. Clinical Medicine and Pharmacology. https://doi.org/10.70731/1m330584
Vancouver
Huang Y, Tan Z, Deng H, Huang H, Tang F. Lymphocyte subset distribution can predict the efficacy of first-line treatment in patients with non-Hodgkin lymphoma. Clinical Medicine and Pharmacology. 2026. doi:10.70731/1m330584
BibTeX
@article{Huang2026,
author = {Huang, Yumei and Tan, Zhenjun and Deng, Hongyu and Huang, Hongjun and Tang, Faqing},
title = {Lymphocyte subset distribution can predict the efficacy of first-line treatment in patients with non-Hodgkin lymphoma},
journal = {Clinical Medicine and Pharmacology},
year = {2026},
doi = {10.70731/1m330584}
}
EUVIMED